Recent Roller Coaster Rides on the OTC (ALPP, QBIO, LGORF)

Today, we are going to look at three of the most rip-roaring movers on the OTC over the past few weeks. The ups and downs have been wild. But, for traders, this is exactly what you want.


Alpine 4 Technologies Ltd (OTCMKTS:ALPP) has had a rough past week of trading action, with shares sinking something like -26% in that time. That said, chart support is nearby and we may be in the process of constructing a nice setup for some movement back the other way. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -58%.

However, all of that comes in the context of a wild ride that has seen as much as 3,900% upside since early October. This has been a wild ride.

Alpine 4 Technologies Ltd (OTCMKTS:ALPP) bills itself as a technology holding company that provides electronic contract manufacturing solutions in the United states.

It also offers automotive technologies, including 6th Sense Auto, a connected car technology that provides various advantages to management, sales, finance, and service departments in the automotive dealership industry to enhance productivity, profitability, and customer retention; and BrakeActive, a safety device that enhances vehicle’s third brake light’s ability to reduce or prevent a rear end collision.

In addition, the company provides fabricated metal parts, assemblies, and sub-assemblies to original equipment manufacturers; and designs, fabricates, and installs dust collectors, commercial ductwork, kitchen hoods, industrial ventilation systems, machine guards, architectural work, water furnaces, and others, as well as specialized spiral duct work.

According to materials, “Alpine 4 Technologies, Ltd (ALPP) is a publicly traded conglomerate that is acquiring businesses that fit into its disruptive DSF business model of Drivers, Stabilizers, and Facilitators. At Alpine 4 we understand the nature of how technology and innovation can accentuate a business. Our focus is on how the adaptation of new technologies even in brick and mortar businesses can drive innovation. We also believe that our holdings should benefit synergistically from each other and that the ability to have collaboration across varying industries can spawn new ideas and create fertile ground for competitive advantages. This unique perspective has culminated in the development of our Blockchain enabled Enterprise Business Operating System called SPECTRUMebos. Four principles at the core of our business are Synergy. Innovation. Drive. Excellence. At Alpine 4, we believe synergistic innovation drives excellence. By anchoring these words to our combined experience and capabilities, we can aggressively pursue opportunities within and across vertical markets. We deliver solutions that not only drive industry standards but also increase value for our shareholders.

Alpine 4 Technologies Ltd (OTCMKTS:ALPP) managed to rope in revenues totaling $7.1M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 47.8%, as compared to year-ago data in comparable terms. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($251K against $18.3M, respectively).


Q BioMed Inc. (OTCMKTS:QBIO) is another roller coaster in play on the OTC. This is an interesting player in the small float small-cap biotech growth space that has projects in motion to attack a major growth market (non-verbal learning disorder) with little competition and big potential. And the chart is screaming that smart traders and investors should do some due diligence here – which is why we put in front of you today.

The company just announced that its technology research partner Mannin Research Inc. presented positive data on a potential new treatment for acute kidney injury (AKI).

According to the release, “The data was presented at the American Society for Nephrology 2019 Annual Meeting held in Washington DC. In the US alone, the cost of hospitalizations for patients with complications arising from AKI can range between $5.4 and $24.0 billion1. There is a significant opportunity to advance a therapeutic solution to treat AK and address a patient population that contributes to 20% of all hospitalizations in the US2.  Current treatments for AKI are mainly supportive and do not treat the underlying condition.”

This is a biomedical acceleration and development company that focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.

The company offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma. Q BioMed Inc. has a partnership with Sphaera Pharma to develop an analog of QBM-001 for pediatric developmental nonverbal disorder; and a collaborative agreement with SRI International to provide formulation development, preclinical development, and early clinical manufacturing of QBM-001.

The stock has suffered a bit of late, with shares taking a hit in recent action, down about -17% over the past week. But that swing is dwarfed by the stock’s burst: Shares of QBIO have powered higher over the past month, rallying roughly 250% in that time on strong overall action.

Q BioMed Inc (OTCMKTS:QBIO) had no reported sales in its last quarterly financial data. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($302K against $2.9M, respectively).


Largo Resources Ltd (OTCMKTS:LGORF) just announced its third quarter 2019 operational and financial results, highlighted by 2,952 tons of vanadium pentoxide produced at a cash operating cost excluding royalties of $2.81 per pound of V2O5. Shares have been all over the place in response.

The context for this announcement is a bit of a bid, with shares acting well over the past five days, up about 18% in that timeframe. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -21%.

The company generated sales of $32.1M, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 9% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($154.8M against $96.1M).

Paulo Misk, President and Chief Executive Officer for Largo, stated: “Operations at the Maracás Menchen Mine performed well in the third quarter 2019 following increased production from the expansion project. Cash operating costs excluding royalties2 were US$2.81 per pound V2O5 in Q3 2019 representing a decrease of 8% over Q3 2018. Although the Company achieved lower operating and unit costs during the quarter, profitability continued to be impacted as a result of lower vanadium prices combined with the Company’s re-measurement of trade receivables / payables as a result of its current off-take agreement and consequently, the Company recorded a net loss of $8.6 million in Q3 2019. The Board realizes that the share price does not currently reflect the business value of the Company and is considering instituting a share repurchase program by way of a Normal Course Issuer Bid.”

Largo Resources Ltd (OTCMKTS: LGORF) bills itself as a natural resource development and exploration company, engages in the acquisition, exploration, and development of mining and exploration properties located in Brazil and Canada. The company primarily explores for vanadium, iron, tungsten, molybdenum, chromite, palladium, and platinum group metals. Its flagship project is the Maracás Menchen Mine that consists of 18 concessions covering an area of 17,690.45 hectares located in Bahia State, Brazil.

Free WordPress Themes, Free Android Games